Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma: A Single-Arm, Multicenter, Phase II Clinical Trial

NCT07514793 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07514793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07514793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma: A Single-Arm, Multicenter, Phase II Clinical Trial
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
April 30, 2029
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelioma